Skip to main content

Table 2 Hematologic and Non-Hematologic Toxicities related to treatment in the first two cycles

From: Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer

   No.patients who experienced toxicity, at maximum grade per patient, at each dose level, mg/mq/die
Toxicity NCIC-CTC grade 1500 1750 2000 2250 2500 2750
Nausea/vomiting 0 2 3 2 2 5 4
  1 1 0 1 1 0 4
  2 0 0 0 0 1 1
  3* 0 0 0 0 0 0
  4* 0 0 0 0 0 0
Diarrhoea 0 2 3 3 2 3 3
  1 1 0 0 0 1 4
  2 0 0 0 1 2 2
  3* 0 0 0 0 0 0
  4* 0 0 0 0 0 0
Liver Toxicity 0 3 2 3 2 6 6
  1 0 1 0 1 0 3
  2 0 0 0 0 0 0
  3* 0 0 0 0 0 0
  4* 0 0 0 0 0 0
Stomatitis 0 3 3 2 2 5 6
  1 0 0 1 1 1 3
  2 0 0 0 0 0 0
  3* 0 0 0 0 0 0
  4* 0 0 0 0 0 0
HFS 0 3 2 3 2 4 4
  1 0 1 0 1 1 3
  2 0 0 0 0 1 2
  3* 0 0 0 0 0 0
  4* 0 0 0 0 0 0
Fatigue 0 2 2 1 0 3 2
  1 0 1 2 2 1 4
  2 1 0 0 1 2 2
  3* 0 0 0 0 0 0
  4* 0 0 0 0 0 1
Leuco-neutropenia 0 2 2 2 2 3 6
  1 0 1 0 0 1 1
  2 1 0 1 1 0 1
  3 0 0 0 0 1 1
  4* 0 0 0 0 0 0
Thrombocytopenia 0 2 3 2 3 5 6
  1 0 0 0 0 1 2
  2 1 0 1 0 0 1
  3 0 0 0 0 0 0
  4* 0 0 0 0 0 0
Anemia 0 1 2 1 2 3 7
  1 0 1 1 1 3 1
  2 2 0 1 0 0 1
  3 0 0 0 0 0 0
  4* 0 0 0 0 0 0